This research shows Capilliposide A decreases renal injury in diabetic nephropathy mice, suggesting TLR4 and NF-κB pathways as therapeutic targets.
Key Points
Capilliposide A significantly reduced renal injury markers and oxidative stress in diabetic nephropathy mice while enhancing antioxidant enzyme levels.
Weekly assessments recorded reductions in serum inflammatory cytokines and improvements in renal function biomarkers with Capilliposide A treatment.
Network pharmacology revealed key targets including NF-κB and TLR4, indicating their roles in inflammation and apoptosis regulation.
Histopathological analysis confirmed that Capilliposide A treatment attenuated kidney damage characteristics of diabetic nephropathy.